Regulatory framework for bringing proteomic IVDs to patients on cards in US
This article was originally published in SRA
The US Food and Drug Administration is looking into how to develop a regulatory framework for validating research-level proteomic assays into in vitro diagnostics (IVDs) that can be used with patients in clinical practice1.
You may also be interested in...
Zolgensma should receive a conditional approval, says the European Medicines Agency’s drug evaluation committee, the CHMP.
The health technology assessment institute is taking a virtual approach to meetings and has said that it can provide free fast-track advice for companies developing novel diagnostics or therapeutics for the coronavirus.
Companies are due to learn this week whether the European Medicines Agency will fast-track its review of their soon-to-be-filed EU marketing applications.